China steadfastly continues to work regulations on biosimilars to help make the market easier to breakthrough, and the recent Priority Review legislation is a case in point. As the industry continues to evaluate cost, risk and incentives for Biosimilar development, new developments to promote R&D and adjustments to approval pathways are designed to help manufacturing and commercialization of biosimilars.
IBC’s 11th Biosimilars Asia is one of 4 conferences part of the 6th Biopharma Development and Production Week in China. It will address the business case, approvals, future manufacturing strategies and commercialisation, in a market that is expected to be worth $20 billion globally by 2022.
- 2 Day Conference: CNY 7,000
- Group of 2 or more delegates: CNY 5,000
- Gala Dinner: CNY 350